AOD 9604 Dosage and Protocol: What the Research Supports The standard research protocol for AOD 9604 is 300 mcg per day, administered via subcutaneous injection
There is no shame in determining that AOD 9604 is not right for you
This therapy utilizes a small molecule known as 5-Amino-1MQ, which targets an enzyme called Nicotinamide N-methyltransferase (NNMT)
Collagen and elastin stimulation Fibroblasts produce collagen and elastin, the structural proteins that keep skin firm and resilient
This boost in energy is particularly beneficial for workout routines, allowing individuals to push beyond their limits without feeling exhausted afterwards
A 12-week randomized trial demonstrated: Average weight loss of 2.6 kg in AOD-9604 group (1 mg/day) versus 0.8 kg in placebo group Preferential reduction in abdominal and visceral fat deposits No adverse effects on carbohydrate metabolism or insulin sensitivity Non-dose-dependent effects, with higher doses (10 mg/day) producing less weight loss than lower doses However, a subsequent 24-week Phase III trial with 502 subjects incorporating intensive diet and exercise showed no statistically significant weight loss compared to placebo, leading to development termination in 2007
